SNZZF (Senzime AB) FFO


SNZZF Senzime AB SNZZF
68 GF Score
Price $0.48
GF Value $1.21
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Senzime AB FFO?

FFO (Funds from operations) only applies to REITs.

SNZZF
68GF Score
Senzime AB SNZZF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Senzime AB (SNZZF) Overvalued in 2026?

Based on GuruFocus' analysis, Senzime AB stock appears to be undervalued. The current stock price of $0.48 is trading 60.5% below its estimated GF Value™ of $1.21. GuruFocus considers Senzime AB to be Possible Value Trap.

Key valuation signals for SNZZF:

  • FFO:
  • GF Value™: $1.21 vs. price of $0.48 (60.5% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the SNZZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Senzime AB Business Description

Other Exchanges SEZI:Sweden6YC:Germany
Address Verkstadsgatan 8, hus 1, Uppsala, SWE, 753 23
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
68GF Score

Get the complete analysis for SNZZF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.48
Price
$1.21
GF Value